Adicet Bio (LTS:0HX7) Issuance of Debt: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HX7 Adicet Bio Inc LTS:0HX7
23 GF Score
Price $8.82
GF Value $0.45
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Issuance of Debt?

Adicet Bio LTS:0HX7 -3.28% 23 Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 23/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Adicet Bio's Issuance of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

Adicet Bio's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Adicet Bio Issuance of Debt Related Terms

Adicet Bio Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Issuance of Debt Chart

Adicet Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Adicet Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0HX7
23GF Score
Adicet Bio Inc LTS:0HX7
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
Adicet Bio (LTS:0HX7) has a Issuance of Debt of $0.00 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's Issuance of Debt too high?
Adicet Bio's current Issuance of Debt is $0.00 Mil. Overall, Adicet Bio has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Issuance of Debt compare to OKYO and GOSS?
Adicet Bio's Issuance of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Adicet Bio and its competitors. Adicet Bio's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $8.82 — trading 1860.3% above its estimated fair value. The current Issuance of Debt is $0.00 Mil. Adicet Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adicet Bio (LTS:0HX7) Overvalued in 2026?

Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued. The current stock price of $8.82 is trading 1860.3% above its estimated GF Value™ of $0.45. GuruFocus considers Adicet Bio to be Significantly Overvalued.

Key valuation signals for LTS:0HX7:

  • Issuance of Debt: $0.00 Mil
  • GF Value™: $0.45 vs. price of $8.82 (1860.3% above fair value)
  • GF Score™: 23/100 with 2 warning signs

No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adicet Bio Business Description

Other Exchanges ACET:USA
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company based in the United States that develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Its approach uses off-the-shelf donor-derived gamma delta T cells engineered with chimeric antigen receptors (CARs) to provide durable activity without the need for patient-specific manufacturing. The company's lead candidate, prulacabtagene leucel (prula-cel), is a CD20-targeting CAR gamma delta T cell therapy in development for autoimmune indications. Adicet is also advancing earlier-stage programs, including ADI-212, a gene-edited, armored candidate targeting prostate-specific membrane antigen (PSMA) for oncology. The company's pipeline spans both autoimmune and solid tumor applications. As a clinical-stage business, Adicet does not yet generate product revenue and funds its research and development through equity financings, partnerships, and other capital sources. Its activities are centered on preclinical and clinical development, regulatory interactions, and manufacturing scale-up.
23GF Score

Get the complete analysis for LTS:0HX7

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.82
Price
$0.45
GF Value